Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

Julie Densmore, MA

Director, Clinical Science and Program Lead

Clinical Development


Julie Densmore, MA, joined PICI in April 2019 as a Clinical Scientist with nearly 20 years of experience in the development of oncology and infectious disease medications. Her career has spanned the full spectrum of clinical research activities beginning with on-site, study monitoring and progressed to the management of global, Phase I – IV research programs resulting in four product approvals along the way. She spent six years working at Novartis Vaccines in Europe supporting the clinical and scientific strategy of the meningitis vaccine portfolio. Prior to Novartis, she managed clinical programs in pneumonia at Cerexa Pharmaceuticals (ceftaroline), in solid tumors at Onyx Pharmaceuticals (immunotherapy; Nexavar), and in lymphoma at Corixa Corporation (radioimmunotherapy; Bexxar). In addition, she supports the clinical development of MDMA-assisted psychotherapy for the Multidisciplinary Association for Psychedelic Studies (MAPS) for the treatment of post-traumatic stress disorder (PTSD). Julie has an M.A. in Research Methodology and Statistics, a B.A. in Psychology, and a certificate in Data Science.